Fix Antibiotic Payment Models To Spur R&D Investment, US FDA’s Gottlieb Says
Executive Summary
Citing need for more ‘pull’ incentives to overcome commercial hurdles, FDA commissioner says a subscription-based fee reimbursement system would provide a foundation for return on investment of new antimicrobials targeting multi-drug resistant pathogens.
You may also be interested in...
Pivot To Video? “Netflix” Rx Pricing Model Plays Well With Media
A subscription model for drug pricing isn’t an entirely new idea, but it is a timely one. If nothing else, the idea of a “Netflix” approach appeals to media savvy audiences.
REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry
As large biopharmaceutical companies continue to exit antibacterial R&D, investments by Novo Holding’s REPAIR Impact Fund and grants from CARB-X can push forward novel therapies for drug-resistant microbial infections.
FDA Commissioner’s Rx For US Biosimilars Market: Reform Contracting Practices And Payment Models
In unveiling the agency’s Biosimilar Action Plan, FDA's Gottlieb continued his pattern of provocative remarks by criticizing brand company practices and payment models that impede biosimilar competition and could ultimately undermine innovation. He also called for more action by the Federal Trade Commission and downplayed the impact interchangeability could have on biosimilar uptake.